Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model by Ozaki, Hidenori et al.
RESEARCH PAPER
Enhancement of metastatic ability by ectopic expression
of ST6GalNAcI on a gastric cancer cell line in a mouse model
Hidenori Ozaki • Hideki Matsuzaki •
Hidenobu Ando • Hiroyuki Kaji • Hayao Nakanishi •
Yuzuru Ikehara • Hisashi Narimatsu
Received: 21 February 2011/Accepted: 9 December 2011/Published online: 8 January 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract ST6GalNAcI is a sialyltransferase responsible for
the synthesis ofsialylTn (sTn)antigen which isexpressed ina
varietyofadenocarcinomasincludinggastriccancerespecially
in advanced cases, but the roles of ST6GalNAcI and sTn in
cancer progression are largely unknown. We generated sTn-
expressinghumangastriccancercellsbyectopicexpressionof
ST6GalNAcI to evaluate metastatic ability of these cells and
prognostic effect of ST6GalNAcI and sTn in a mouse model,
and identiﬁed sTn carrier proteins to gain insight into the
function of ST6GalNAcI and sTn in gastric cancer progres-
sion.Agreenﬂuorescent protein-taggedhumangastric cancer
cell line was transfected with ST6GalNAcI to produce sTn-
expressingcells,whichweretransplantedintonudemice.STn-
positive gastric cancer cells showed higher intraperitoneal
metastatic ability in comparison with sTn-negative control,
resulting in shortened survival time of the mice, which
was mitigated by anti-sTn antibody administration. Then,
sTn-carrying proteins were immunoprecipitated from culture
supernatants and lysates of these cells, and identiﬁed MUC1
and CD44 as major sTn carriers. It was conﬁrmed that MUC1
carries sTn also in human advanced gastric cancer tissues.
Identiﬁcation of sTn carrier proteins will help understand
mechanisms of metastatic phenotype acquisition of gastric
cancer cells by ST6GalNAcI and sTn.
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Introduction
Sialyl Tn (sTn) antigen, one of the most well-known can-
cer-associated glycan structures, which is expressed in a
large proportion of gastric, colorectal, ovarian, breast,
pancreatic and other adenocarcinoma tissues, and is
detected in sera and/or other body ﬂuids of patients with
these cancers [1–9]. STn expression is correlated with poor
prognosis of patients [1–4, 7, 10], and thus it is used as a
serum or tissue marker for these tumors. In gastric cancer,
sTn expression is also correlated with peritoneal metastasis
[11, 12], a major cause of recurrence, which is thought to
originate from intraperitoneal free tumor cells. Thus, sTn is
viewed as a favorable target for detection of intraperitoneal
free tumor cells and peritoneal micrometastases, as well as
prediction of prognosis of patients, although only recently
developed, RT-PCR-based detection methods [13–15] are
the most sensitive for this purpose to date.
STn is synthesized by transferring a sialic acid in an
a2,6-linkage to an N-acetylgalactosamine linked to a serine
or threonine residue (Tn antigen) by ST6GalNAcI [16].
SincetheexpressionofsTniscorrelatedwith,orinducedby,
the expression of ST6GalNAcI in some colorectal, gastric,
and breast cancer cell lines [16–18], the emergence of sTn is
thought to be partly due to aberrant expression of ST6Gal-
NAcI, with or without concomitant decrease or loss of other
glycosyltransferases which compete with ST6GalNAcI for
their substrate [19].
Positive correlations of sTn expression with cancer
aggressiveness and poor prognosis of the patients have
provoked great interest in the functional analyses on sTn.
Induction of sTn in a mouse mammary carcinoma cell line
led to morphological changes, impaired proliferation, and
decreasedmigrationonﬁbronectinandhyaluronicacidstrata
[20]. A human gastric cancer cell line showed decreased
cell–cell aggregation, elevated adhesion and migration
activity on ECM proteins, and increased invasive capability
ininvitroassayusingMatrigel,allofwhichwereblockedby
an anti-sTn mAb, HB-STn [21]. Further, transplantation of
an ST6GalNAcI-transfected, sTn-positive human breast
cancer cell line into mice showed increased tumorigenicity
and tumor size in comparison to mock transfectants [22].
However, the molecular mechanisms underlying these phe-
notypic changes of the cells still need to be elucidated.
Inaddition,therolesofsTnandST6GalNAcIinperitoneal
metastasis of gastric cancer are not well understood.
Previously, we established a convenient in vivo monitoring
system for micrometastases in nude mice using GFP-tagged
human gastric cancer cell lines [23, 24]. In the present study,
we applied this in vivo monitoring system to elucidate the
roles of ST6GalNAcI and sTn in gastric cancer peritoneal
metastasis. We showed that ectopic expression of ST6Gal-
NAcI in a gastric cancer cell line induced surface expression
ofsTnandresultedinenhancedintraperitonealmetastasisand
tumorgrowth,andshortenedsurvivaltime,thelatterofwhich
was mitigated by administration of anti-sTn mAb. We also
found that the major carrier proteins for sTn in these cells are
MUC1 and CD44, suggesting the possible involvement of
these sTn-carrying glycoproteins in acquisition of this meta-
static phenotype by these gastric cancer cells.
Materials and methods
Cell lines
A GFP-tagged human gastric cancer cell line, GCIY-EGFP
[23],aderivativesublineofGCIYwhichhadbeenoriginally
obtained from the RIKEN Cell Bank (Tsukuba, Japan), and
its transfectants were maintained in RPMI1640 (Sigma, St.
Louis, MO) supplemented with 10% FBS, 100 units/ml
penicillin, and 100 lg/ml streptomycin (Invitrogen, Carls-
bad, CA) in a humidiﬁed 5% CO2 incubator at 37C.
DNA transfection and isolation of sTn-expressing cells
To obtain sTn-expressing GCIY-EGFP cells [23], cells were
transfected with an ST6GalNAc I-expressing vector, pXLS
[16], using Lipofectamine 2,000 reagent (Invitrogen). Trans-
fectants were selected with geneticin (G418; 0.6 mg/ml,
Sigma)inRPMI1640supplementedwith10%FBS,100units/
ml penicillin, and 100 lg/ml streptomycin. Three days after
transfection, cells were harvested and stained for sTn with
anti-sTn mAb, B72.3, and allophycocyanin (APC)-labeled
goat anti-mouse Ig (BD Biosciences, San Diego, CA). Cells
positive for both APC and GFP were collected by a FACS
(FACSaria;BDBiosciences),assTn-expressingcells(GCIY/
6L) and maintained in RPMI1640 supplemented with 10%
FBS,100units/mlpenicillin,and100 lg/mlstreptomycin.As
a negative control, GCIY-EGFP cells were transfected with
pXSS, which expressed a truncated inactive form of
ST6GalNAc I [16], and the transfectants were selected with
geneticin in RPMI1640 supplemented with 10% FBS, 100
units/ml penicillin, and 100 lg/ml streptomycin (GCIY/6S).
Mice
Seven- to eight-week-old male athymic nude mice of the
KSN strain were purchased from Shizuoka Laboratory
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pathogen-free conditions at Aich Cancer Center Research
Institute.
Peritoneal metastasis assay and anti-sTn antibody
treatment
As described previously [23], exponentially growing cells
were harvested with trypsin/EDTA (Invitrogen), washed
and resuspended in Hanks’ balanced salt solution. Cell
suspensions containing 4 9 10
6 GCIY/6L or GCIY/6S
cells were injected into the peritoneal cavity of the reci-
pient mice. Peritoneal metastasis was externally monitored
in living mice under illumination of blue light twice a week
until the end point. Some of the recipients were sacriﬁced
at 5 weeks after injection to clearly visualize intraperito-
neal distribution of cancer cells and the resected tumor
masses were measured.
For antibody treatment, the recipient mice were intra-
peritoneally injected with 4 9 10
6 GCIY/6L cells. Then,
one milligram of puriﬁed anti-sTn mAb B72.3 or control
mouse IgG (Sigma) was intraperitoneally injected twice a
week for 3 weeks (total 6 times) starting from 2 days after
injection of tumor cells.
All animal experiments were conducted according to the
ethical guidelines for animal experiments of the institutions
which met the standard as deﬁned by the UKCCR (UK Co-
ordinating Committee on Cancer Research) guidelines and
the safety guidelines for DNA manipulation experiments.
Preparation of anti-sialyl Tn mAb, B72.3
The B72.3 hybridoma cell line [25, 26] was obtained from
ATCC. The hybridoma cells were adapted to serum-free
medium (Hybridoma-SFM; Invitrogen) to remove proteins
from FBS in the normal media. The culture supernatants
were then collected and B72.3 mAb was afﬁnity-puriﬁed
with protein G or protein A Sepharose beads (GE Health-
care, Buckinghamshire, UK).
Immunoprecipitation
For sTn, puriﬁed B72.3 mAb was conjugated covalently to
the Sepharose beads with CNBr-activated Sepharose 4B
(GE Healthcare). For MUC1 and CD44 pull-downs, anti-
MUC1 mAb VU4H5, and anti-CD44 polyclonal antibody
H-300 (Santa Cruz Biotechnology, Santa Cruz, CA), were
immobilized to beads in the Protein G Sepharose 4 Fast
Flow kit (GE Healthcare). Cells in culture were grown to
near conﬂuency, and culture supernatants were collected
and centrifuged to obtain clear supernatants. Cells on
dishes or frozen tissue sections were lysed with RIPA
buffer (50 mM Tris–HCl, pH7.3, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1%SDS) containing protease inhibitor cocktail (Com-
plete Mini, EDTA-free; Roche Diagnostics GmbH,
Mannheim, Germany) and centrifuged to prepare clear
lysates. These cell culture supernatants and lysates were
mixed with antibody-ﬁxed Sepharose beads and rotated
overnight at 4C. After extensive washing with RIPA
buffer, bound proteins were extracted from the precipitates
by incubating in SDS sample buffer at 98C for 5 min and
then subjected to SDS-PAGE.
Western blotting
Protein samples were applied to SDS-PAGE and separated
proteins were transferred onto polyvinylidene diﬂuoride
membranes (Immune-Blot PVDF; Bio-Rad Laboratories,
Hercules, CA). After blocking with 5% skim milk in Tris-
buffered saline containing 0.1% Tween20 (TBS-T), the
blot was incubated with the primary antibody appropriately
diluted in TBS-T and then with the HRP-conjugated sec-
ondary antibody. Detection of the proteins of interest was
done by the Western Lightning Chemiluminescence
Reagent Plus (PerkinElmer, Boston, MA).
Protein identiﬁcation by mass spectrometry
ProteinsampleswereappliedtoSDS-PAGEandthegelswere
silver-stained with SilverQuest Silver Staining Kit (Invitro-
gen). Protein bands were excised and destained, followed by
reduction and alkylation. Then the proteins were in-gel
digested with sequencing grade modiﬁed trypsin (Promega,
Madison, WI). The tryptic peptides were extracted, absorbed
totheC18resinpackedinaZipTip(Millipore,Bedford,MA),
and eluted with elution buffer (50% acetonitrile, 0.1% triﬂu-
oroacetic acid (TFA)). After mixing with equal volume of
CHCA (a-cyano-4-hydroxycinnamic acid) matrix solution
(10 mg/ml CHCA dissolved in 50% acetonitrile, 0.1%TFA),
eluted peptides were spotted onto an Anchorchip sample tar-
get plate and analyzed by ultraﬂex MALDI-TOF/TOF mass
spectrometer (Bruker Daltonics, Bremen, Germany). The
MS-Fit database search engine of the ProteinProspector web
site was used for protein identiﬁcation.
Clinical samples
Gastric cancer tissues were collected from patients with
advanced gastric cancer who had completed a written
informed consent at Aichi Cancer Center Hospital after
Institutional Review Board approval. All experiments
using human tissues were conducted after the approval by
the institutional ethics committees at Aichi Cancer Center
and National Institute of Advanced Industrial Science and
Technology (AIST).
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Survival period were analyzed by the Kaplan–Meier
method and compared using the log-rank test. The statis-
tical signiﬁcance of difference in metastatic tumor weight
between groups was determined by applying Student’s t
test. Differences in the incidence between the groups were
analyzed by Fisher’s exact test. Signiﬁcant differences
were considered as P\0.05.
Results
Induction of sTn-expression in a gastric cancer cell line
transfected with ST6GalNAcI
A number of human gastric cancer cell lines have been
established to date. However, gastric cancer cell lines with
endogenous expression of sTn have not yet been estab-
lished, although sTn expression is often observed in gastric
cancer tissues. Thus, we introduced the ST6GalNAcI
expression vector pXLS [16] into a GFP-tagged gastric
cancer cell line, GCIY-EGFP [23], to drive sTn synthesis
in the cells. Flow cytometric analysis showed that a sub-
population positive for both GFP and sTn emerged (Fig. 1,
left, enclosed by a rectangle). These cells were resorted by
FACS and expanded as sTn-expressing GCIY-EGFP cells
(GCIY/6L), which express sTn on the cell surface at a
moderate level as a whole (Fig. 1, right). As a negative
control, GCIY-EGFP cells were transfected with pXSS,
which encoded a truncated inactive form of ST6GalNAcI
[16], and the transfectants were selected with geneticin and
expanded as sTn-negative GCIY/6S cells (data not shown).
GCIY/6L cells show high metastatic ability and poor
outcome when transplanted in nude mice
To evaluate the effects of ST6GalNAcI and sTn expression
on in vivo metastatic ability, GCIY/6L and GCIY/6S cells
were injected into the abdominal cavity of athymic nude
mice (4 9 10
6 cells per mouse). At 5 weeks after injection,
the mice were sacriﬁced to visualize the peritoneal
metastasis under blue light illumination and the tumor
masses were weighed. In mice injected with GCIY/6L, a
larger number of metastatic foci were formed on the peri-
toneum in comparison to GCIY/6S (Fig. 2a, b), indicating
that ST6GalNAcI expression enhances attachment of the
cancer cells to the peritoneum. Total tumor weights in the
peritoneal cavity were also signiﬁcantly larger in mice
injected with GCIY/6L (Fig. 2c), suggesting cancer cell
growth promotion by ST6GalNAcI, as well as peritoneum
attachment of cancer cells. In addition, survival time of
mice was signiﬁcantly shorter for GCIY/6L-transplanted
mice than GCIY/6S-transplanted ones (Fig. 2d). These
results clearly demonstrate that ST6GalNAcI expression
enhances in vivo metastatic ability and mortality of the
recipient mice in this assay system. To date, sTn synthesis
is the only function of ST6GalNAcI as an enzyme [16],
thus it is likely that this phenotypic change is due to
induced expression of sTn, although unknown function of
ST6GalNAcI might be involved.
Effects of B72.3 administration on metastasis, tumor
growth, and survival time of the recipient mice
To conﬁrm the involvement of sTn in the peritoneal
metastasis in this model, we tried to suppress the peritoneal
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Fig. 1 Establishment of an sTn-expressing human gastric cancer cell
line. An GFP-tagged human gastric cancer cell line, GCIY-EGFP,
was transfected with the ST6GalNAcI-expression vector, pXLS, and
analyzed by a ﬂow cytometer for sTn and GFP dual expression. A cell
population positive for both sTn and GFP is enclosed by a rectangle
and termed as GCIY/6L (left). GCIY/6L cells were sorted by a cell
sorter and re-analyzed by a ﬂow cytometer for sTn expression (right,
a solid line) together with a negative control (a dotted line)
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123metastasis of GCIY/6L and to prolong survival time of the
mice by administration of anti-sTn mAb, B72.3. One
milligram of puriﬁed B72.3, or puriﬁed mouse IgG was
injected into the peritoneal cavity of the recipient mice
twice a week for 3 weeks after injection of GCIY/6L cells
(4 9 10
6 per mouse). As shown in Fig. 3a, the number and
the sizes of peritoneal metastatic foci tended to be smaller
in B72.3-treated mice than in control mice. In accordance
with this observation, incidence of jaundice due to the
obstruction of biliary tract, which is associated with the
progression of tumor invasion, was signiﬁcantly lower in
B72.3-treated mice than controls, while incidence of asci-
tes accumulation was not different between the two groups
(Fig. 3c). However, we did not detect signiﬁcant difference
in metastatic tumor weights between B72.3-treated and
control groups in this experimental condition (Fig. 3b).
Nevertheless, survival time of the mice was signiﬁcantly
longer for B72.3-treated mice than controls (Fig. 3d).
These results suggest possible involvement of sTn in the
augmented metastatic property of gastric cancer cells in
this mouse model.
MUC1 and CD44 are major carriers of sTn
on GCIY/6L
To gain insight into the molecular mechanisms of
enhancement of peritoneal metastasis by sTn, we deter-
mined the carrier protein(s) of sTn. sTn carrier proteins
were immunoprecipitated with B72.3 from the culture
supernatants and the cell lysates of GCIY/6L and GCIY/6S
cells, and subjected to western blot analysis with the same
mAb. From the GCIY/6L supernatant, 2 major bands of
*110 and[250 kDa were detected along with some minor
bands (Fig. 4a). Also from the GCIY/6L cell lysate, 2 major
bands of *120 and [250 kDa, as well as a few minor
bands, were found (Fig. 4a). For the *120 kDa band found
in the GCIY/6L lysate, a speciﬁc mass spectrum was
obtained from the silver-stained gel slice and found to be
derived from CD44 (data not shown). Western blot analysis
using CD44-speciﬁc polyclonal antibody conﬁrmed this
result (Fig. 4b, right). In addition, a faint CD44 signal of
*110 kDa was also detected in the GCIY/6L supernatant
by long exposure (data not shown), which is thought to be a
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Fig. 2 Increased metastasis and mortality in GCIY/6L-transplanted
mice. a, b Recipient nude mice were i.p. injected with 4 9 10
6 GCIY/
6L or GCIY/6S cells, and were subjected to laparotomy to visualize
metastatic cells under UV light at 5 weeks after transplantation. The
number of metastatic foci was deﬁnitively larger in GCIY/6L-
transplanted mice (b) than in GCIY/6S-transplanted mice (a). c At
this time point, peritoneal tumor masses were resected and weighed.
GCIY/6L-derived tumor masses were signiﬁcantly larger in weight
than those of GCIY/6S. P\0.005; n = 7 (GCIY/6L) and n = 5
(GCIY/6S). Bars represent standard errors (SE). d Overall survival of
the recipient mice as depicted by the Kaplan-Meier method. Survival
time was signiﬁcantly shorter for GCIY/6L-transplanted mice (closed
circles and a solid line) than for GCIY/6S-transplanted mice (open
circles and a dotted lines). P\0.0005; n = 6 (GCIY/6L) and n = 7
(GCIY/6S)
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123truncated form of CD44. These results indicate that CD44 is
one of the major sTn carriers in GCIY/6L cells. On the
contrary, no signiﬁcant mass spectrum was obtained from
the bands of [250 kDa in both the supernatant and the
lysate (data not shown). This may be due to resistance of
these molecules to trypsin digestion conferred by dense
glycosylation. Their large size, putative heavy glycosyla-
tion, and preferential recognition of consecutive sTn cluster
by B72.3 [27], suggest that these molecules may be mucins.
To conﬁrm this idea, the blot used above was examined for
mucin expression by re-probing with a series of anti-mucin
antibodies. We found that only anti-MUC1 mAb reacted to
the same-sized bands as the sTn signals at [250 kDa
(Fig. 4b, left), but the antibodies to other mucins (MUC2, 3,
4. 5AC, 5B and 16) did not (data not shown), indicating that
MUC1 is the other major sTn carrier in GCIY/6L cells. By
the reciprocal immunoprecipitation-western blot analyses
further conﬁrmed that CD44 and MUC1 carry sTn(Fig. 4c).
In summary, these results clearly demonstrate that MUC1
and CD44 are the major carriers of sTn in GCIY/6L cells.
MUC1 carries sTn in human gastric cancer tissues
In GCIY/6L cells, sTn expression was obtained by ectopic
expression of ST6GalNAcI. Like GCIY, currently avail-
able gastric cancer cell lines do not express endogenous
sTn, although sTn expression is often detected in gastric
cancer tissues, indicating that in vitro culture and/or clon-
ing processes affect the expression status of ST6GalNAcI
and sTn. Thus, sTn carrier proteins in human gastric cancer
tissues may differ from those identiﬁed in GCIY/6L. To
determine whether MUC1 and CD44 carry sTn also in
human, frozen gastric cancer tissues from 4 cases were
sliced and lysed in RIPA buffer to obtain tissue lysates.
After centrifugation, clear supernatants were subjected to
immunoprecipitation-western blot analysis using B72.3.
Broad sTn bands at high molecular weights were detected
in 3 of 4 cases (Fig. 5a, left). When the blot was re-probed
with anti-MUC1 mAb, the MUC1-speciﬁc band was
detected only in one case (5-C), but not in the others
(Fig. 5a, right). In case of 5-C, the MUC1-speciﬁc diffuse
band overlapped with but was clearly distinct from the sTn
diffuse bands (Fig. 5a). This difference may result from the
recognition preference of the mAb for un- or under-gly-
cosylated MUC1 tandem repeats. When the same tissue
lysates were immunoprecipitated with anti-MUC1 mAb,
sTn-speciﬁc signals were detected at approximately the
same size range as in the MUC1 immunoprecipitation
(Fig. 5b). In contrast, CD44 was not detected in any of
these cases (data not shown). These results indicate that
MUC1 is an sTn carrier in some advanced human gastric
cancer tissues.
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Fig. 3 Effects of B72.3 administration on metastatic ability and
survival of the recipient mice. a GFP-ﬂuorescence view of peritoneal
metastasis. Intraperitoneal dissemination such as peri-bile duct
invasion (arrow), a cause of jaundice was reduced by B72.3
treatment. b Metastatic tumor weights excised from control mouse
IgG-treated and B72.3-treated mice. c The incidence of jaundice was
signiﬁcantly lower in B72.3-treated mice than in IgG-treated control.
*P\0.05. d Overall survival of the GCIY/6L-transplanted recipient
mice as depicted by the Kaplan-Meier method. The recipients
administered with B72.3 (open circles) survived signiﬁcantly longer
than those with control mouse IgG (closed circles). P\0.05; n = 6
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In this study, we established ST6GalNAcI transfectant of
gastric cancer cells with surface expression of sTn and
provided the ﬁrst demonstration of ST6GalNAcI and sTn
involvement in intraperitoneal metastasis in a mouse
model. Our results suggest that glycoform alteration of
carrier proteins to sTn may be involved in the enhanced
peritoneal metastasis observed in our animal model. The
mechanisms of this enhancement in metastasis are not
entirely clear, but may include accelerated cell prolifera-
tion, enhanced migratory activity, altered adhesiveness to
target matrices or cells, and/or decreased apoptotic activity.
These possibilities are supported by the reports showing
that expression of sTn induced phenotypic change of the cells
in vitro and in vivo [18–22]. In fact, we observed a larger
number of metastatic foci in GCIY/6L cell-transplanted mice,
indicating enhancement of cancer cell attachment to the
peritoneum.
In addition, we found that a large proportion of sTn is
carried by MUC1 and CD44 in GCIY/6L cells, suggesting
that glycoform alteration of these molecules or unidentiﬁed
carrier proteins to sTn may be involved in the enhanced
peritoneal metastasis observed in our animal model.
MUC1 is a membrane-bound mucin and enhanced
expression is detected in many types of epithelial and non-
epithelial tumors [28]. It has been reported that MUC1
expression level or content is positively correlated with the
extent of cancer progression or disease stage [29, 30]. In
addition, overexpression of MUC1 confers tumorigenic
potential on the cells [31–33]. Although the molecular
basis of MUC1 tumorigenicity is not clearly known, phe-
notypic changes of MUC1-overexpressing cells are thought
to be partly due to steric hindrance to the interaction
between cell adhesion molecules by its protruding structure
above the cell surface and by its dense negative charges
from sialic acids on the termini of a large number of
O-glycans [34, 35]. In addition, glycosylation patterns of
MUC1 are also changed during tumor formation. In breast
cancer cell lines, MUC1 O-glycans are mostly core 1-based
or Tn antigen, in contrast to normal mammary glands
which express core 2-based glycans on MUC1 [36].
Modiﬁcation of MUC1 with sTn was reported in gastric
and breast cancer cell lines transfected with ST6GalNAcI
[21, 22], and in pancreatic and colon cancer cell lines in
which exogenous FLAG-tagged MUC1 was introduced
[37]. In the former two cases [21, 22], alteration of cellular
characteristics was observed, although molecules other
than MUC1 were also modiﬁed with sTn. In our report,
MUC1 modiﬁcation with sTn was concomitant with
enhancement of peritoneal metastatic activity, suggesting
that sTn modiﬁcation of MUC1 was involved in this pro-
cess. It is not known how sTn modiﬁcation of MUC1
causes such a phenotypic change, however, two possible
mechanisms may be involved. First, glycoform change of
MUC1 may alter conformation of the peptide backbone as
previously reported [38, 39]. Second, structural change in
glycan may cause changes in interaction with other mole-
cules such as lectins, i.e. loss of interaction with one lectin
and gain of interaction with another, although sTn-recog-
nizing endogenous lectins have not yet been identiﬁed to
date. Although further studies are required to clarify these
questions, sTn-MUC1 may be a target molecule for gastric
cancer cell detection.
CD44 is a type I transmembrane glycoprotein involved
in cell–cell and cell–matrix interactions and cancer
metastasis through interaction with extracellular matrix
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mAb. b The blot used in (a) was stripped and re-probed with anti-
MUC1 mAb (left) or anti-CD44 polyclonal antibody (right). c Cell
lysates and culture supernatants of GCIY/6L (L) and GCIY/6S
(S) were immunoprecipitated with anti-MUC1 mAb (left) or anti-
CD44 polyclonal antibody, and analyzed by western blot using B72.3
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123molecules [40]. Involvement of CD44 in metastasis was
ﬁrst reported by Gunthert & colleagues [41]. In the report,
a variant of CD44 was expressed almost exclusively in
metastatic tissues and cancer cell lines, and the expression
of this variant converted a non-metastatic cell line to
metastatic. It was also reported that the variant-speciﬁc
anti-CD44 antibody treatment blocked metastasis [42].
Although the mechanisms by which CD44 variants affect
metastasis are not yet fully understood, interacting mole-
cules such as ERM proteins (ezrin, radixin, moesin), which
regulate cell motility and shape [43] and bind to CD44
cytoplasmic tail in active states [44, 45], are thought to be
involved. Besides alternative splicing, aberrant glycosyla-
tion of CD44 also affects cellular phenotypes such as
tumorigenicity [46, 47]. It was reported that CD44 carries
sTn in a human breast cancer cell line transfected with
ST6GalNAcI, although the roles of sTn-carrying CD44 in
enhanced subcutaneous tumor growth have not yet been
elucidated [22]. As also shown by our results, enhancement
of intraperitoneal metastatic activity was parallel with sTn-
modiﬁcation of CD44. These results suggest possible roles
of sTn-modiﬁed CD44 in tumorigenicity and intraperito-
neal metastasis in vivo, as well as those of MUC1. How-
ever, sTn-modiﬁed CD44 was not detected in gastric
cancer tissues in the clinical samples used here. This may
be because the glycosylation pathway of CD44 may differ
from that of MUC1 in tumor cells in gastric cancer tissues
or due to the small sample size in our study, thus, extensive
studies with much more gastric cancer cases may be nec-
essary to detect sTn-modiﬁed CD44 in human tissues.
In this study, we observed prognostic improvement of
recipient mice by repeated injection of anti-sTn mAb
(Fig. 3), suggesting anti-tumor and anti-metastatic effects
of this mAb. Reduced incidence of jaundice by the anti-
body-treatment may support this idea. However, no
signiﬁcant difference in total tumor weights was observed
between anti-sTn mAb-treated and control IgG-treated
mice at necropsy in this experimental condition. The
results also suggest that administration dose of the mAb
and dosing protocol should be improved. Or the role of sTn
in the metastatic process may still remain partial, which
leads to the observed limited effects of mAb administra-
tion. For example unknown functions of ST6GalNAcI may
be involved through mechanisms other than sTn synthesis.
In summary, this experimental model will provide a
valuable system to study roles of ST6GalNAcI and sTn in
gastric cancer cell properties including metastasis.
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